Skip to main content

Table 3 Associations between p53 protein status and clinicopathological parameters.

From: Prognostic and predictive value of TP53mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial

  

Wild-type p53

N = 435

p53 mutated*

N = 85

Pvalue**

Missense mutation

N N = 64****

Pvalue***

Truncating mutation

N = 19****

Pvalue***

Age

< 35

31 (7.1%)

3 (3.5%)

0.0045

2 (3.1%)

0.0061

1 (5.2%)

0.6432

 

35-49

219 (50.3%)

36 (42.3%)

 

26 (40.6%)

 

10 (52.6%)

 
 

50-65

175 (40.2%)

38 (44.7%)

 

29 (45.3%)

 

7 (36.8%)

 
 

> 65

10 (2.3%)

8 (9.4%)

 

7 (10.9%)

 

1 (5.2%)

 

Menopausal status

Premenopausal

248 (57.0%)

38 (44.7%)

0.0768

27 (42.2%)

0.0800

11 (57.9%)

0.7279

 

Postmenopausal

163 (37.5%)

43 (55.3%)

 

33 (51.6%)

 

8(42.1%)

 
 

Not known

24 (5.5%)

4 (4.7%)

 

4 (6.3%)

 

0

 

Body Mass Index (BMI)

Nonobese (< 30)

352 (80.9%)

66 (77.6%)

0.487

52 (81.3%)

1.0000

12 (63.2%)

0.0744

 

Obese (> = 30)

83 (19.1%)

19 (22.3%)

 

12 (18.8%)

 

7 (36.8%)

 

Histopathology

Infiltrating ductal ca.

347 (79.8%)

77 (90.6%)

0.0256

57 (89.1%)

0.0866

18 (94.7%)

0.2922

 

Infiltrating lobular ca.

51 (11.7%)

2 (2.3%)

 

2 (3.1%)

 

0

 
 

Other

37 (8.5%)

6 (7.1%)

 

5 (7.8%)

 

1 (5.3%)

 

Tumor size (pT)

T1

129 (29.6%)

22 (25.9%)

0.6070

15 (23.4%)

0.3858

6 (31.6%)

0.6489

 

T2

268 (61.6%)

58 (68.2%)

 

45 (70.3%)

 

13 (68.4%)

 
 

T3

34 (7.8%)

4 (4.7%)

 

3 (4.7%)

 

0

 
 

Missing

4 (0.9%)

1 (1.2%)

 

1 (1.6%)

 

0

 

Number of positive lymph nodes

1-3

230 (52.9%)

42 (49.4%)

0.5587

34 (53.1%)

1.0000

8 (42.1%)

0.4825

 

> = 4

205 (47.1%)

43 (50.6%)

 

30 (46.9%)

 

11 (57.9%)

 

Histopathological grade

G1

34 (7.8%)

2 (2.3%)

< 0.0001

1 (1.6%)

2.977E-04

1 (5.3%)

0.0078

 

G2

208 (47.8%)

22 (25.9%)

 

18 (28.1%)

 

3 (15.8%)

 
 

G3

186 (42.7%)

60 (70.6%)

 

44 (68.8%)

 

15 (79.0%)

 
 

Missing

7 (1.6%)

1 (1.2%)

 

1 (1.6%)

 

0

 

ER/PgR status

ER+/PgR+

322 (74.0%)

49 (57.6%)

< 0.0001

42 (65.6%)

0.0415

6 (31.6%)

1.424E-04

 

ER+/PgR-

28 (6.4%)

4 (4.7%)

 

2 (3.1%)

 

2 (10.5%)

 
 

ER-/PgR-

67 (15.4%)

31 (36.5%)

 

19 (29.7%)

 

11 (57.9%)

 
 

Other

18 (4.1%)

1 (1.2%)

 

1 (1.6%)

 

0

 

HER2 status

HER2 -

350 (80.4%)

64 (75.3%)

0.1848

48 (75.0%)

0.2145

15 (79.0%)

0.5460

 

HER2+

71 (16.3%)

20 (23.5%)

 

15 (23.4%)

 

4 (21.0%)

 
 

Missing

14 (3.2%)

1 (1.2%)

 

1 (1.6%)

 

0

 

IHC subtypes

Luminal A

76 (36.8%)

8 (9.4%)

< 0.0001

6 (9.4%)

0.0155

2 (10.5%)

1.592E-04

 

Luminal B

270 (62.1%)

45 (52.9%)

 

38 (59.4%)

 

6 (31.6%)

 
 

HER2

25 (5.7%)

7 (8.2%)

 

4 (6.3%)

 

2 (10.5%)

 
 

Triple-negative

42 (9.6%)

24 (28.2%)

 

15 (23.4%)

 

9 (47.4%)

 
 

Missing

22 (5.0%)

1 (1.2%)

 

1 (1.6%)

 

0

 
  1. *Any non-synonymous variation in exon 5 to 8. **P value-chi-square test: comparison of wild-type p53 and p53 mutated. ***P value-Fisher's exact test: comparison of wild-type p53 and p53 mutation (missense or truncating). ****Of 85 p-53 mutations, 83 were classified as mutated (N = 64) or truncating (N = 19), and 2 were not subclassified (see Methods section). ER, estrogen receptor; IHC, immunohistochemistry; PgR, progesterone receptor.
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us